Clinical trial
Biological Therapy in Treating Children With Refractory or Recurrent…
NCT00003750 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003750 |
|---|---|
| Title | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors |
| Official title | A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | hu14.18-IL2 fusion protein |
| Enrollment | 28 |
| Start date | Oct 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 8, 2014 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: